BAP1


BAP1 stands for BRCA1 Associated Protein-1, a protein found inside cells throughout the body. It is located on chromosome 3 and acts as a tumor suppressor, meaning it helps prevent cells from growing uncontrollably and turning into cancer. Loss of BAP1 activity or expression in cells is often associated with certain aggressive cancers and can help pathologists predict how a tumor might behave over time.

What types of normal cells and tissues express BAP1?

BAP1 is expressed in nearly all normal tissues in the body. Under normal conditions, BAP1 protein is located primarily inside the cell nucleus, where it plays a critical role in controlling cell growth, repairing damaged DNA, and regulating cell death. Healthy tissues commonly used as controls for BAP1 testing include skin, pancreas, normal melanocytes, optic nerve nuclei, and ganglion cells of the retina.

How do pathologists test for BAP1?

Pathologists test for BAP1 using a specialized laboratory technique called immunohistochemistry. This test uses antibodies that attach specifically to the BAP1 protein in cells. Pathologists examine tissue samples under a microscope to look for the presence or absence of BAP1 staining in the cell nucleus. Tumors that lose nuclear staining (negative) are considered to have lost BAP1 expression, which can indicate a more aggressive disease.

Typically, pathologists classify tumors as BAP1 negative if fewer than 33% of tumor nuclei stain positive, and BAP1 positive if 33% or more nuclei stain positive.

What types of benign (non-cancerous) tumors express BAP1?

Most benign tumors retain normal BAP1 expression and show strong nuclear staining. However, certain benign melanocytic tumors (moles) associated with germline BAP1 mutations may show loss of BAP1 expression. These are often Spitzoid or epithelioid melanocytic tumors, which can have atypical microscopic features resembling melanoma, making them challenging to diagnose correctly.

What types of malignant (cancerous) tumors show loss of BAP1 expression?

Loss of BAP1 expression is seen in several aggressive cancers, including:

  • Uveal melanoma (a type of eye cancer): Loss of BAP1 occurs in about 40–60% of cases and is associated with a worse prognosis and higher risk of spreading.

  • Malignant mesothelioma (a cancer affecting the lining of the lungs or abdomen): Approximately 66% of mesotheliomas show loss of BAP1 expression.

  • Renal cell carcinoma (kidney cancer), lung adenocarcinoma, breast cancer, and certain types of skin cancers (cutaneous melanomas) may also show BAP1 mutations or loss of expression.

In contrast, metastatic melanoma originating from the skin typically retains BAP1 expression (positive staining), which helps differentiate it from metastatic melanoma originating from the eye (uveal melanoma), which frequently shows loss of BAP1.

Why do pathologists test for BAP1?

Pathologists test for BAP1 expression to help:

  • Predict prognosis: Loss of BAP1 in cancers like uveal melanoma indicates a higher risk of aggressive behavior and a worse outcome.

  • Differentiate between benign and malignant conditions: Loss of BAP1 expression helps distinguish malignant mesothelioma from benign (reactive) mesothelial proliferations.

  • Identify hereditary cancer syndromes: Germline (inherited) BAP1 mutations are associated with a hereditary cancer syndrome that includes increased risks for melanoma, mesothelioma, renal cell carcinoma, and other cancers.

  • Clarify the origin of metastatic melanoma: Loss of BAP1 helps differentiate metastatic uveal melanoma (commonly negative for BAP1) from metastatic skin melanoma (usually positive).

Prognostic significance of BAP1

Loss of BAP1 is strongly associated with poor prognosis in cancers like uveal melanoma, mesothelioma, and certain other tumors. In uveal melanoma, tumors lacking nuclear BAP1 expression are associated with significantly shorter survival and higher risk of metastasis compared to those retaining BAP1.

Questions for your doctor

  • Was BAP1 tested on my biopsy or surgical specimen, and what were the results?

  • Does the loss or retention of BAP1 expression affect my diagnosis or prognosis?

  • Is there a need for genetic testing to determine if I have a hereditary risk associated with BAP1 mutations?

  • How does my BAP1 result influence my treatment plan?

  • If I have a BAP1-associated tumor, do I need additional cancer screening for other types of cancers?

  • Are there specific follow-up steps or additional testing recommended based on my BAP1 status?

A+ A A-